Latest From Targovax ASA
Oncolytic virus-based therapies which act as immune activators will be the only candidates in the Norwegian biotech’s pipeline from now on.
Dutch biotech Amphera has progressed into late-stage clinical studies with dendritic cells activated with an allogeneic lysate of tumor cell lines; the dendritic cells are expected to have a therapeutic effect in patients with mesothelioma, a tumor with few treatment options.
Targovax terminates development of TG01 in pancreatic cancer patients after data unveiled at ASCO fundamentally alters development preconditions for its TG vaccine program.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Large Molecule
- Therapeutic Areas
- Targovax AS
- Western Europe
- Parent & Subsidiaries
- Targovax ASA
- Senior Management
Oystein Soug, CEO
Erik Digman Wiklund, CFO
Magnus Jaderburg, CMO
Michael Bogenstaetter, PhD, CBO
- Contact Info
Phone: 213 98 810
Lilleakerveien 2 C
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.